A Texas molecular diagnostic firm - Castle Biosciences - has raised $1.5 million, according to a regulatory filing. 

The company's goal is to treat people afflicted by rare or orphan cancers. According to submissions with the Securities & Exchange Commission, Castle Biosciences has raised around $1 million and above annually since 2009.

In 2008, it raised a little more than $400,000. 

The company's institutional investors are Mountain Group Capital and Affiliates, Long Fellow Venture Partners I and the State of Texas Emerging Technology Fund. 

Its commercially available tests are to diagnose eye cancer (uveal melanoma), thymoma, and brain cancer (glioblastoma and lower-grade gliomas). Castle Biosciences' efforts are also directed at other cancers including mesothelioma. In September, the company issued a press release announcing that it had an exclusive license for a mesothelioma test developed at Brigham and Women's Hospital in Boston.
 

- By Arundhati Parmar, Senior Editor, MD+DI

Related Content

Maker of Prostate Cancer Screening Imaging Device Seeks $2.5 million

Startup that Makes Sensor to Track Use of Asthma Inhaler Raises $7 million in Series A